A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Pietrantonio Filippo
Main Facility: Oncologia Medica Gastroenterologica
Drug: HER3-DXd=patritumab deruxtecan
Pathologies: Intestinal cancer
ClinicalTrials.gov: Read the details about clinical trials
This is a Phase 1/2, non-randomized, multicenter, open-label study evaluating HER3-DXd monotherapy in patients with selected metastatic GI cancers. Three initial cohorts with high unmet medical need in the refractory setting will be studied: colorectal cancer (CRC), biliary tract cancer (BTC), and hepatocellular carcinoma (HCC). These tumors were chosen due to the high need for effective treatments and the expected benefit/risk balance of HER3-DXd in these populations.
Approximately 130 eligible participants will be randomly distributed into the following cohorts:
• Cohort 1: 2L CRC (approximately 40 participants)
• Cohort 2: 2L+ BTC (approximately 40 participants)
• Cohort 3: 2L HCC (up to approximately 50 participants, including the dose-escalation phase)
• Cohort 4: 2L GA (up to approximately 50 participants)
The primary objectives of the study are:
• Evaluate the objective response rate (ORR) according to RECIST 1.1, assessed by BICR.
• Evaluate the safety and tolerability of HER3-DXd, with monitoring for adverse events (AEs) and serious adverse events (SAEs), and discontinuation of the intervention for AEs.
Last update: 16/07/2026